Related Experiment Video

Updated: Dec 27, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

990

Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic

Felice Pepe1,2, Veronica Balatti1,2

  • 1Department of Cancer Biology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA.

Journal of Clinical Medicine
|February 27, 2020
PubMed

Insights

Novel targeted therapies and immunotherapies show promise for chronic lymphocytic leukemia (CLL). Non-coding RNAs (ncRNAs) like microRNAs and tsRNAs are key biomarkers for diagnosing, monitoring, and predicting drug resistance and relapse in CLL patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Targeted therapies (BTK inhibitors, Bcl2 blockers) and immunotherapies (monoclonal antibodies, CAR-T cell therapy) have advanced CLL treatment.
  • Drug resistance and disease relapse remain significant challenges in managing chronic lymphocytic leukemia (CLL).

Purpose of the Study:

  • To review recent advancements in targeted therapy and immunotherapy for CLL.
  • To discuss the critical role of non-coding RNAs (ncRNAs) in CLL development and progression.
  • To explore the potential of ncRNAs as biomarkers and therapeutic targets in CLL.

Main Methods:

  • Literature review of recent discoveries in CLL targeted therapy and immunotherapy.
  • Analysis of studies investigating the role of non-coding RNAs (ncRNAs) in CLL.
  • Synthesis of information on ncRNAs as diagnostic, prognostic, and predictive biomarkers.

Main Results:

  • Non-coding RNAs, including microRNAs (miRs) and tRNA-derived small-RNAs (tsRNAs), are implicated in CLL pathogenesis.
  • These ncRNAs show potential as biomarkers for early diagnosis, disease monitoring, and predicting treatment response.
  • ncRNAs may offer novel targets for developing new drugs and combination regimens for CLL.

Conclusions:

  • Targeted therapies and immunotherapies have improved CLL outcomes, but resistance and relapse persist.
  • ncRNAs represent a promising area for developing novel diagnostic tools and therapeutic strategies for CLL.
  • Further research into ncRNAs could lead to personalized treatment approaches for CLL patients, improving drug selection and patient management.
Keywords:
CLLimmunotherapymir-15/16targeted therapyvenetoclax

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.9K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.2K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.6K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Types of RNA01:20

Types of RNA

Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
8.6K
Types of RNA01:23

Types of RNA

Overview
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in the regulation of gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA...
72.2K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K